{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-275086","form_type":"8-K","ticker":"HCA","cik":"0000860730","company_name":"HCA Healthcare, Inc.","filed_at":"2026-06-18T13:12:19+00:00","discovered_at":"2026-06-18T13:13:00.251453+00:00","generated_at":"2026-06-18T13:13:03.825270+00:00","sec_items":["5.02"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"HCA Healthcare EVP & Chief Clinical Officer Michael Cuffe to step down Aug 31, 2026","bullets":["Dr. Michael Cuffe to step down as EVP and Chief Clinical Officer effective August 31, 2026.","He will continue in a transitional role with the company until February 2027.","Eligible for benefits under executive severance policy and applicable incentive plans.","No successor has been named at this time."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-275086","json":"https://secwatch.observer/filing/0001193125-26-275086.json","markdown":"https://secwatch.observer/filing/0001193125-26-275086.md","text":"https://secwatch.observer/filing/0001193125-26-275086.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/860730/000119312526275086/0001193125-26-275086-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/860730/000119312526275086/d163825d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-18T13:13:03.825270+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"164ce2d5d3","claim":"Michael Cuffe departed as Executive Vice President and Chief Clinical Officer at HCA Healthcare, Inc..","evidence_excerpt":"On June 15, 2026, Dr. Michael Cuffe and HCA Healthcare, Inc. (the “Company”) agreed that Dr. Cuffe will step down as Executive Vice President and Chief Clinical Officer effective August 31, 2026, and thereafter continue in a transitional role with the Company until February 2027.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/860730/000119312526275086/0001193125-26-275086-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"step down"},{"label":"Role","value":"Executive Vice President and Chief Clinical Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}